Effect of hemoperfusion using polymyxin B-immobilized fiber on IL-6, HMGB-1, and IFN gamma in a neonatal sepsis model.
To evaluate effects of polymyxin B direct hemoperfusion (PMX-DHP) on a neonatal sepsis cecal ligation and perforation (CLP) model, in 24 anesthetized and mechanically ventilated 3-d-old piglets, 16 were assigned to CLP and an arteriovenous extracorporeal circuit from 3 h until 6 h post-CLP, with a PMX-column in PMX-DHP-treated group (8 piglets) and 8 as sham. Plasma lipopolysaccharide (LPS) was measured at before CLP and at 3 and 9 h. Changes in mean systemic blood pressure (mSBP), mean pulmonary blood pressure, serum IL-6, tumor necrosis factor alpha, interferon gamma, and highly mobile group-1 box protein were measured before CLP and at 1, 3, 6, and 9 h. LPS was lower in the sham and PMX-DHP groups than in the control at 9 h. The mSBP was higher in the sham and PMX-DHP groups than in the control at both 6 h. IL-6 was lower in the sham and PMX-DHP groups than in the control at 6 h. HMGB-1 was lower in the PMX-DHP group than in the control at 6 h. IFN-gamma was only detected in the control group at 9 h. Survival times in the PMX-DHP group were longer than in the control. Thus, PMX-DHP improved septic shock in a neonatal septic model.
Hussein
Mohamed Hamed
MH
Department of Pediatrics, Neonatology and Congenital Disorders, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. drmhamed@yahoo.com
Kato
Takenori
T
Sugiura
Takahiro
T
Daoud
Ghada A
GA
Suzuki
Satoshi
S
Fukuda
Sumio
S
Sobajima
Hisanori
H
Kato
Ineko
I
Togari
Hajime
H
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001424:Bacterial Infections / Q000188:drug therapy*; D001794:Blood Pressure; D001831:Body Temperature; D004195:Disease Models, Animal; D024243:HMGB1 Protein / Q000378:metabolism*; D006464:Hemoperfusion; D007371:Interferon-gamma / Q000378:metabolism*; D015850:Interleukin-6 / Q000378:metabolism*; D008070:Lipopolysaccharides / Q000737:chemistry / Q000378:metabolism; D011112:Polymyxin B / Q000008:administration & dosage* / Q000737:chemistry; D011550:Pseudomonas aeruginosa / Q000378:metabolism; D018805:Sepsis / Q000188:drug therapy* / Q000517:prevention & control; D013234:Stem Cells; D013552:Swine; D013997:Time Factors
D000900:Anti-Bacterial Agents; D024243:HMGB1 Protein; D015850:Interleukin-6; D008070:Lipopolysaccharides; D007371:Interferon-gamma; D011112:Polymyxin B